Mitoxantrone in malignant melanoma.
Twenty-nine patients with metastatic malignant melanoma without prior chemotherapy and 36 patients refractory to prior chemotherapy received mitoxantrone (5 mg/m2/week). No patient achieved a partial response. The dose-limiting toxic effect was granulocytopenia. Mitoxantrone is ineffective in malignant melanoma.
D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D008942:Mitoxantrone; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology
D000880:Anthraquinones; D000970:Antineoplastic Agents; D008942:Mitoxantrone